Effects of p38 Inhibitor AZD7624 in Corticosteroid Resistant Asthma

Summary

This is a double-blind, placebo controlled 4 week crossover study to investigate the efficacy and safety of AZD7624 (an inhaled p38 inhibitor) in corticosteroid resistant (CR) asthmatics. For the purpose of this study 10 symptomatic CR asthma patients with a FEV1% predicted \<80% and normal bronchodilator response, 10 CS asthmatics and 10 healthy controls will be recruited.

Timeline

Start

2017-01

Primary completion

2019-02-25

Completion

2019-02-25

Drugs

Indications